[CAS NO. 356547-88-1] Belimumab

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [356547-88-1]

Catalog

HY-P9952

Brand

MCE

CAS

356547-88-1

DESCRIPTION [356547-88-1]

Overview

MDL	-
Molecular Weight	-
Molecular Formula	-
SMILES	[Belimumab]

For research use only. We do not sell to patients.

Summary

Belimumab (LymphoStat B) is a human IgG1λ monoclonal antibody that inhibits B-cell activating factor (BAFF) . Belimumab can be used for systemic lupus erythematosus (SLE) research ^[1] .

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT03207958	Washington University School of Medicine\|GlaxoSmithKline\|American Cancer Society, Inc.	Graft Vs Host Disease\|Graft-versus-host-disease	May 16, 2018	Phase 1
NCT01484496	Human Genome Sciences Inc., a GSK Company\|GlaxoSmithKline	Systemic Lupus Erythematosus	November 16, 2011	Phase 3
NCT00583362	Human Genome Sciences Inc., a GSK Company\|GlaxoSmithKline	Systemic Lupus Erythematosus	May 4, 2005	Phase 2
NCT00712933	Human Genome Sciences Inc., a GSK Company\|GlaxoSmithKline	Systemic Lupus Erythematosus	May 30, 2008	Phase 3
NCT05588830	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	Lupus Nephritis\|Belimumab\|Telitacicept	October 20, 2022
NCT01762852	GlaxoSmithKline	Glomerulonephritis, Membranous	April 2013	Phase 2
NCT05069051	University Hospital Tuebingen\|GlaxoSmithKline	Chronic Lymphoid Leukemia in Relapse	January 19, 2022	Phase 2
NCT04179032	GlaxoSmithKline	Systemic Lupus Erythematosus	November 28, 2019	Phase 2
NCT05154734	Tianjin Medical University General Hospital	NMO Spectrum Disorder	October 30, 2021	Phase 1\|Phase 2
NCT00732940	Human Genome Sciences Inc.\|GlaxoSmithKline	Systemic Lupus Erythematosus	October 2008	Phase 2
NCT01610492	GlaxoSmithKline	Glomerulonephritis, Membranous	July 1, 2012	Phase 2
NCT03591380	University of Wisconsin, Madison\|GlaxoSmithKline\|American College of Surgeons	Kidney Transplantation	May 14, 2019	Phase 2
NCT05604742	xuna\|Nanfang Hospital of Southern Medical University	cGVHD	January 1, 2022	Phase 1\|Phase 2
NCT03747159	Leiden University Medical Center\|Dutch Kidney Foundation\|GlaxoSmithKline	Lupus Erythematosus, Systemic	October 1, 2018	Phase 3
NCT03312907	GlaxoSmithKline	Systemic Lupus Erythematosus	March 1, 2018	Phase 3
NCT02347891	Northwell Health\|GlaxoSmithKline	Myositis	January 2015	Phase 2\|Phase 3
NCT05338190	Assistance Publique - Hôpitaux de Paris\|GlaxoSmithKline	Primary Immune Thrombocytopenia (ITP)	June 1, 2022	Phase 3
NCT02270970	Oklahoma Medical Research Foundation\|GlaxoSmithKline	Systemic Lupus Erythematosus	October 2014	Phase 4
NCT01583530	Human Genome Sciences Inc.\|GlaxoSmithKline	Healthy	February 2011	Phase 1
NCT02880852	GlaxoSmithKline	Systemic Lupus Erythematosus	January 23, 2017	Phase 1
NCT04660565	Peking Union Medical College Hospital	IgG4-related Disease	January 2021	Phase 4
NCT02119156	GlaxoSmithKline	Systemic Lupus Erythematosus	May 13, 2014	Phase 3
NCT01480596	GlaxoSmithKline	Myasthaenia Gravis	April 2013	Phase 2
NCT00931086	Human Genome Sciences Inc., a GSK Company\|GlaxoSmithKline	Rheumatoid Arthritis	April 2009
NCT04570306	Biomedical Research Foundation, Academy of Athens	Systemic Lupus Erythematosus	December 31, 2020
NCT00410384	Human Genome Sciences Inc.\|GlaxoSmithKline	Systemic Lupus Erythematosus	December 2006	Phase 3
NCT03949855	National Institute of Allergy and Infectious Diseases (NIAID)\|Immune Tolerance Network (ITN)\|GlaxoSmithKline\|PPD\|Rho Federal Systems Division, Inc.	Membranous Nephropathy\|Nephrotic Syndrome	December 18, 2019	Phase 2
NCT01597622	GlaxoSmithKline\|Human Genome Sciences Inc.	Systemic Lupus Erythematosus	June 11, 2012	Phase 3
NCT04136145	GlaxoSmithKline	Systemic Lupus Erythematosus	October 28, 2019	Phase 1
NCT01536379	GlaxoSmithKline	Transplantation, Organ	September 2013	Phase 2
NCT02631538	GlaxoSmithKline	Sjogren´s Syndrome	February 17, 2016	Phase 2
NCT04447053	National University Hospital, Singapore\|GlaxoSmithKline	Systemic Lupus Erythematosus	November 8, 2021	Phase 4
NCT00071812	Human Genome Sciences Inc.	Arthritis, Rheumatoid	December 2003	Phase 2
NCT02124798	GlaxoSmithKline	Systemic Lupus Erythematosus	May 20, 2014	Phase 2
NCT04893161	First Affiliated Hospital Xi´an Jiaotong University	Systemic Lupus Erythematosus	January 1, 2023	Phase 4
NCT00583557	Human Genome Sciences Inc.	Rheumatoid Arthritis	January 2005	Phase 2
NCT02260934	National Institute of Allergy and Infectious Diseases (NIAID)\|Immune Tolerance Network (ITN)	Lupus Nephritis	July 9, 2015	Phase 2
NCT04097561	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health Clinical Center (CC)	Idiopathic CD4 Lymphopenia	January 13, 2020	Phase 1
NCT03967925	Rachel Jones\|GlaxoSmithKline\|Medical Research Council\|Imperial College London\|University College, London\|Newcastle University\|University of Glasgow\|University of Cambridge\|Cambridge University Hospitals NHS Foundation Trust	ANCA Associated Vasculitis\|Granulomatosis With Polyangiitis	February 1, 2019	Phase 2
NCT05020782	University of Turin, Italy	Antiphospholipid Syndrome	June 1, 2022	Phase 2\|Phase 3
NCT00424476	Human Genome Sciences Inc.\|GlaxoSmithKline	Systemic Lupus Erythematosus	May 2007	Phase 3
NCT05262686	Peking University People´s Hospital	Systemic Lupus Erythematosus	April 1, 2022	Phase 3
NCT01705977	GlaxoSmithKline	Systemic Lupus Erythematosus	November 27, 2012	Phase 4
NCT04767698	Johns Hopkins University\|GlaxoSmithKline	Multiple Sclerosis	October 1, 2021	Phase 2
NCT01532310	GlaxoSmithKline\|PPD	Systemic Lupus Erythematosus	July 16, 2012
NCT01142011	Cancer Trials Australia\|Human Genome Sciences Inc.	Symptomatic Waldenstroms Macroglobulinaemia	November 2009	Phase 2
NCT01597492	Human Genome Sciences Inc., a GSK Company\|GlaxoSmithKline	Systemic Lupus Erythematosus	May 31, 2012	Phase 4
NCT01663623	Human Genome Sciences Inc., a GSK Company\|GlaxoSmithKline	Vasculitis	March 20, 2013	Phase 3
NCT03244059	University of Alabama at Birmingham\|GlaxoSmithKline	Chronic Obstructive Pulmonary Disease\|Emphysema	August 9, 2018	Phase 2
NCT01914770	GlaxoSmithKline\|Human Genome Sciences Inc.	Systemic Lupus Erythematosus	July 2009
NCT04629144	Assistance Publique - Hôpitaux de Paris	Vasculitis\|Cryoglobulinemia	March 1, 2021	Phase 2
NCT00071487	Human Genome Sciences Inc.	Lupus Erythematosus, Systemic	October 2003	Phase 2
NCT01639339	Human Genome Sciences Inc., a GSK Company\|GlaxoSmithKline	Lupus Nephritis	July 12, 2012	Phase 3
NCT00724867	Human Genome Sciences Inc., a GSK Company\|GlaxoSmithKline	Systemic Lupus Erythematosus	August 2008	Phase 3
NCT01345253	GlaxoSmithKline\|Human Genome Sciences Inc.	Systemic Lupus Erythematosus	May 23, 2011	Phase 3
NCT01649765	GlaxoSmithKline\|Human Genome Sciences Inc., a GSK Company	Systemic Lupus Erythematosus	September 7, 2012	Phase 2
NCT01440361	GlaxoSmithKline	Purpura, Thrombocytopaenic, Idiopathic	March 2013	Phase 2
NCT01670565	Hospital for Special Surgery, New York\|Human Genome Sciences Inc.	Systemic Sclerosis	August 2012	Phase 2
NCT00657007	Human Genome Sciences Inc.	Systemic Lupus Erythematosus	February 2002	Phase 1
NCT04515719	RenJi Hospital	Systemic Lupus Erythematosus	March 19, 2021	Phase 4
NCT01632241	Human Genome Sciences Inc., a GSK Company\|GlaxoSmithKline	Systemic Lupus Erythematosus	February 19, 2013	Phase 4
NCT01160666	Assistance Publique - Hôpitaux de Paris\|Human Genome Sciences Inc.	Sjögren´s Syndrome	March 2010	Phase 2
NCT01858792	Human Genome Sciences Inc., a GSK Company\|GlaxoSmithKline	Lupus Erythematosus, Discoid	May 2011
NCT03844061	Hospital for Special Surgery, New York\|GlaxoSmithKline	Systemic Sclerosis	July 29, 2019	Phase 2
NCT02500251	E. Steve Woodle\|GlaxoSmithKline\|University of Cincinnati	Renal Transplant Rejection	June 2015	Phase 1\|Phase 2
NCT04908865	GlaxoSmithKline	Systemic Lupus Erythematosus	October 21, 2021	Phase 4
NCT01025193	University of Pennsylvania\|Human Genome Sciences Inc.	Desensitization	February 2010	Phase 2
NCT02284984	Leiden University Medical Center\|Dutch Kidney Foundation\|ZonMw: The Netherlands Organisation for Health Research and Development	Lupus Erythematosus, Systemic	March 2014	Phase 2
NCT05585671	RenJi Hospital	Whether Belimumab Could Reduce 2-year Risk of New-onset Lupus Nephritis	June 1, 2023
NCT04956484	Peking Union Medical College Hospital	Lupus Erythematosus, Systemic	September 1, 2021	Phase 4
NCT03125486	GlaxoSmithKline	Systemic Lupus Erythematosus
NCT01894360	GlaxoSmithKline	Systemic Lupus Erythematosus	October 14, 2013	Phase 1
NCT03543839	Northwell Health\|GlaxoSmithKline	Lupus Erythematosus, Systemic\|Lupus Erythematosus	September 15, 2020	Phase 4

Appearance

Solid

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References

[1] Hannah A Blair, et al. Belimumab: A Review in Systemic Lupus Erythematosus. Drugs. 2018 Mar;78(3):355-366.